// App-Quantinova.ai

SAT0221 (2018) : Effect of tofacitinib on reducing pain in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

Researchers

Presenter

  • A. Ogdie

Principal Investigators

  • K. de Vlam

  • I. B. McInnes

  • P. J. Mease

  • P. Baer

  • T. Lukic

  • K. Kwok

  • C. Wang

  • M.-A. Hsu

  • A. Maniccia

Medical Centers

  • Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

  • KU Leuven, Leuven, Belgium

  • University of Glasgow, Glasgow, United Kingdom

  • Swedish Medical Center and University of Washington School of Medicine, Seattle, WA

  • Baer Weinberg MPC, Scarborough, ON, Canada

  • Pfizer Inc, New York, NY

  • Pfizer Groton CT United States

Locations

  • United States

  • Belgium

  • United Kingdom

  • Canada

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

  • Musculoskeletal

Disease

  • Ankylosing spondylitis

  • Rheumatoid arthritis

  • Psoriatic arthritis

  • Inflammatory Arthritis

Biomarkers

  • Fas receptor

Drug/Treatment

  • Tasocitinib

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • II

Study Id's

  • NCT00847613

  • NCT00856544

  • NCT00853385

  • NCT00960440

  • NCT01877668

  • NCT01882439

  • NCT01786668

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved